文献速递脊柱外科

巴曲酶、氨甲环酸及其联合应用在腰椎融合手术中减少失血的有效性与安全性

Effectiveness and Safety of Batroxobin, Tranexamic Acid and a Combination in Reduction of Blood Loss in Lumbar Spinal Fusion Surgery.
PubMed 文献 · Spine (Phila Pa 1976) · 2018-01-01

这项前瞻性随机双盲安慰剂对照试验将100例腰椎单节段融合手术患者分为四组,分别接受巴曲酶、氨甲环酸、两药联合或安慰剂。结果显示,巴曲酶组和联合组术中失血量显著低于安慰剂组,术后引流量组间差异有统计学意义,而输血需求和深静脉血栓发生率无显著差异。

要点

  • 巴曲酶组和联合组术中失血量显著低于安慰剂组(P<0.001)。
  • 四组术后引流量差异有统计学意义(P<0.001)。
  • 输血需求、血红蛋白变化及深静脉血栓发生率组间无显著差异。

核心结论

  • 巴曲酶及巴曲酶联合氨甲环酸可显著减少腰椎融合手术患者围手术期失血量。

研究设计与样本

  • 前瞻性随机双盲安慰剂对照试验,纳入100例患者,随机分为巴曲酶组、氨甲环酸组、联合组和安慰剂组。

主要发现

  • 术中平均失血量:巴曲酶组268.32±62.92 mL,氨甲环酸组340.72±182.75 mL,联合组256.96±82.64 mL,安慰剂组448.44±205.86 mL;安慰剂组术中失血量显著高于巴曲酶组和联合组(P<0.001)。
  • 术后手术部位引流量:巴曲酶组218.00±100.54 mL,氨甲环酸组260.40±100.85 mL,联合组191.00±87.84 mL,安慰剂组320.00±125.83 mL;组间差异有统计学意义(P<0.001)。
  • 液体管理(P=0.751)、输血(P=1.000)、术前血红蛋白(P=0.090)、术后血红蛋白(P=0.134)及深静脉血栓(P=1.000)组间均无统计学显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: A prospective randomized double blind placebo controlled trail. OBJECTIVE: To evaluate and compare the efficacy and safety of batroxobin (botropase), tranexamic acid (TXA), and their combination in reduction of perioperative blood loss in lumbar spine single level fusion surgeries. SUMMARY OF BACKGROUND DATA: Spinal surgeries are associated with significant blood loss leading to perioperative anemia and increased need for allogenic transfusion. TXA competitively inhibits plasmin and batroxobin converts fibrinogen to fibrin and theoretically their combination is synergistic. Though TXA is widely studied in controlling blood loss, there is little information on use of batroxobin and their combination. Thus, we aimed to study effect and safety of individual drugs and their combination in controlling blood loss in spinal surgery. METHODS: Hundred patients were randomized into four groups. Group B received batroxobin, group T received TXA, group BT received batroxobin and TXA and group P received placebo. Outcomes assessed are intraoperative and postoperative blood loss, hematocrit, allogenic blood transfusion, and deep vein thrombosis (DVT), postoperatively. RESULT: Mean intraoperative blood loss in Group B, T, BT, and P were 268.32 ± 62.92 mL, 340.72 ± 182.75 mL, 256.96 ± 82.64 mL, and 448.44 ± 205.86 mL, respectively. Postoperative surgical site drain collection in Group B, T, BT, and P were 218.00 ± 100.54 mL, 260.40 ± 100.85 mL, 191.00 ± 87.84 mL, and 320.00 ± 125.83 mL, respectively. Intraoperative blood loss of Group P was statistically higher than Groups B and BT (P < 0.001). Mean postoperative surgical site drain collection was statistically significant (P < 0.001). No statistically significant differences in fluid administration (P = 0.751), blood transfusion (P = 1.000), preoperative and postoperative hemoglobin (P = 0.090, P = 0.134, respectively), and deep vein thrombosis (P = 1.000). CONCLUSION: Batroxobin and combination of batroxobin with tranexamic acid significantly reduced perioperative blood loss when compared with placebo. LEVEL OF EVIDENCE: 2.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Nagabhushan RM, Shetty AP, Dumpa SR, et al. Effectiveness and Safety of Batroxobin, Tranexamic Acid and a Combination in Reduction of Blood Loss in Lumbar Spinal Fusion Surgery. Spine (Phila Pa 1976). 2018. PMID: 28678111. doi:10.1097/BRS.0000000000002315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。